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ABSTRACT 
Psoriasis is a dermatological disorder consists of   abnormal multiplied skin cells   than normal one. It causes the thickness of skin is increased 
and forms a   red patches and white scales in the lesion. The disease causing several adverse problems in patient's i.e. adverse physical and 
mental conditions that are same to   malignancies, heart disorder, diabetes mellitus, and depression. This review focus on the novel therapies 
for psoriasis that have emerged recently. It contains different classes of drugs (local, systemic) with different mechanism of action. Psoriasis 
cure rate is very low, so this regimens goal is to relieve symptoms as long as possible with a good benefit/risk ratio. In this review, the  new 
regimens that target pathways and other steps in the pathogenesis of psoriasis are discussed, including IL12/IL-23, IL-17, IL-22, TNF- , JAK 
inhibitor etc.The prevalence of disease in worldwide is 0.6 to 4.8%. Cyclosporine and methotrexate are the example of systemic treatment 
regimen for the management of psoriasis but their toxicity is very high, nephrotoxicity, hepatotoxicity and pulmonary fibrosis are the toxicities 
of methotrexate and cyclosporine. But in the case of novel regimens the toxicity is very low as compared to existing regimens . This article was 
designed to compare the treatment efficacy of novel regimen with already available treatment options for psoriasis.  
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Psoriasis is a chronic dermatological disorder produced by a 
hyperactive auto immune system. Flaking, inflammation of 
skin, thickening of skin, formation of white silvery and red 
patches on the skin is the symptoms of psoriasis. The 
prevalence of disease in worldwide is 0.6 to 4.8%. The 
disease causing several adverse problems in patients i.e. 
adverse physical and mental conditions that are same to 
malignancies, heart disorder, diabetes mellitus, and 
depression. The disease are classified into plaque, gestate, 
pustule, and erythrodermic psoriasis.  
This common dermatitis is extremely variable in clinical 
manifestations by morphology and extent of involvement, 
ranging from innocuous lesion to widespread life 
threatening pustule and erythrodermic forms. It can affect 
any area including palms, soles and genitalia. Several 
treatment modalities are currently available and many 
guidelines have been formulated all over the world. The 
treatment is mainly suppressive aimed at inducing 
remissions and improving the patient’s quality of life. [1] 
Routinely for limited psoriasis, coal tar, topical 
corticosteroids, dithranol, calcipotriol and topical 
photochemotherapy are administered. For extensive 
psoriasis UVB, PUVA, PUVASOL, methotrexate, hydroxyurea, 
acitretin and cyclosporine are preferred. Disease modifying 
agents such as etanercept, infliximab and other biological 
may be required in resistant cases. 
The immune system involved a major part in the 
development of psoriasis, this concept utilized to the 
discovery and development of several novel regimen  for the 
treatment of  psoriasis, i.e. which drug that target to the IL-
17, IL-23  and drug       that are involved in intracellular 
signaling   pathways i.e. Janus Kinase (JAK) inhibitor and 
phosphodiesterase-4 (PDE-4) inhibitor.[1] 
This article was designed to compare the treatment efficacy 
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1. JAK inhibitor JTE-052: 
Janus kinases (JAKs) are involved in progression of psoriasis. 
They are act by included in several inflammatory cytokine 
signaling pathways in psoriasis. So JAK inhibitors considered 
as a most important therapeutic option for psoriasis. JAK 
inhibitor like JTE-052 inhibitsthe type 1 T helper cells, type 
2 T helper cells and type17 T helper cells immune responses. 
These responses are involved in  chronic dermal diseases. [2] 
JTE-052 inhibits the skin inflammation and suppresses the 
inflammatory cell activation in various type of psoriasis. The 
efficacy of oral JTE-052 is very rapid in skin inflammation 
compared to oral cyclosporine and methotrexate in 
psoriasis.[3] 
Cyclosporine and methotrexate are the example of systemic 
treatment regimen for the management of psoriasis, but 
their toxicity is very high, nephrotoxicity, hepatotoxicity and 
pulmonary fibrosis are the toxicities of methotrexate and 
cyclosporine so their usage is limited. But in the case of JAK 
inhibitor there have a no reports of organ toxicities. So JAK 
inhibitors are therefore most important systemic 
therapeutic option for psoriasis, with fewer side effects than 
other systemic therapies.[4,5] 
2. Tetherin, Type I interferon biomarker and 
Ustekinumab, an interleukin 12/23 p40 monoclonal 
antibody: 
Tetherin is a novel type I interferon biomarker also known 
as bone marrow stromal antigen 2 is a protein in human it 
encoded by the BST2 gene. It act on the blood leukocytes and 
trapping interferon level and combining with Ustekinumab 
an interleukin 12/23 p40 monoclonal antibody,  is  used in 
the treatment of psoriasis. Ustekinumab is interfering with 
triggering of the inflammatory responses in psoriasis by 
suppression of certain cytokines in the body, i.e. it blocks the 
interleukin12 /23 which help in activation of certain T-
cells.[5,6] 
3. Human interleukin-23 monoclonal antibody – 
Guselkumab: 
Generalized pustular psoriasis (GPP) and Erythrodermic 
psoriasis (EP) are rare severe types of psoriasis and their 
treatment is very difficult. So guselkumab is very effective in 
this subtype of psoriasis. 
Guselkumab selectively inhibits Interleukin -23 by 
specifically binding with P19 subunit. Interleukin-23 is an 
inflammatory cytokines, it stimulate the CD4 and T-helper 
cells and involved in inflammatory processes and induces 
psoriasis plaque formation. Guselkumab proved 
symptomatic improvements in psoriasis patients. Elevated 
levels of IL-17A, T-helper-17 producing cells in skin lesion 
are reported in patients with GPP and EP. IL-23 blocking by 
guselkumab may result in inhibiting the level of Th17 cells 
and IL-cells in psoriasis patients.[7,8] 
The mechanism of action of guselkumab is selectively 
blocking the interleukin 23. It may result in preventing the 
action of pathogenic T-helper cells and decreasing the level 
of IL-17A in skin lesion.[9,10] 
4. Indirubin: A new topical traditional Chinese 
medicine: 
Indirubin is a active constituent of Indigo naturalis, is a 
Chinese herb also known as Qing Dai. Recent clinical studies 
demonstrated that they are effective in mild to 
moderatepsoriasis. They are effective in psoriasis by which 
preventing the proliferation of cells and inducing cell 
differentiation. By interacting with aryl hydrocarbon 
receptorthey inhibit cell-cycle-related kinases and cell 
signalingproteins such as STAT3. It also inhibitsinterferon-  
is a pro inflammatory cytokines.[11] 
Indirubin is administered as topical, and they aremore safe 
and effective therapy than topicalcorticosteroids in the 
treatment of psoriasis and not required safety concerns 
comparing with topically administered corticosteroids. 
Indirubin effective in psoriasis by different mechanism of 
actionand totally different from other topical therapies.[12] 
5. Syl930 –A newly developed sphingosine -1- 
phosphate (SIP1) modulator: 
A newly developed sphingosine-1-phosphate (SIP1) 
modulator Syl930 is studied and used in psoriasis patients. 
The orally administered Syl930 inhibits proliferation and 
inflammation in psoriasis patients. So we reveal that Syl930 
is an important treatment option for psoriasis. 
Activation of SIP1 contributes to the immune reaction by 
recirculation of lymphocytes.SIP also inhibitsepidermal cells 
growth and it leads to keratinocytes differentiation. So SIP1 
signaling pathway is promising treatment option for 
psoriasis treatment.[13,14] 
Syl930 is studied in various animal models for 
demonstrating their effects in psoriasis treatment. 
i. In sodium lauryl sulphate applied mouse skin 
irritation model: 
This animal model mimics the early skin symptoms of 
psoriasis. Topically applied SLS in mice increase then 
thickness of the skin due to inflammation. Oral 
administration of Syl930 decreases the thickening of skin of 
mice. So it’s strongly supporting the Syl930 in the treatment 
of psoriasis.[15,16] 
ii. In mouse tail assay: 
In psoriasis patients changes in skin including 
hyperkeratosis and loss of granular layer. The orally 
administered Syl930 elevate the granular layer scales 
compared to the control group in the study. 
iii. In propranolol treated Guinea pig psoriasis model: 
Both ears of guinea pig were treated with 5% propranolol 
solution twice a day induce psoriasis, it leads to 
elevatedPara keratosis, acanthuses, diminished granular 
layer and elongation of rete ridges and dilated capillaries are 
seen in ears of guinea pig.so Syl930 at a dose of 1.0mg/kg 
reduced the Para keratosis and acanthosis, and increased 
granular layer and decreased thickening in the epidermis.[17] 
6. Ixekizumab: 
Ixekizumab (IXE) is a monoclonal antibody it selectively 
bindsand blocks IL-17A, and is discovered and used in the 
treatment of psoriasis. Ixekizumab have good safety and 
efficacy profile compared to other biological in the treatment 
of psoriasis. Itadministered as a subcutaneous injection and 
rapid clinical improvement in psoriasis.[18] 
Ixekizumab is the humanized monoclonal immunoglobulin 
G(IgG) that act by specifically targetting and inhibiting IL-
17A and it lead to the inhibiting inflammatory changes in 
psoriasis patients. Psoriasis patients have elevated levels of 
IL-17A.[19,20] 
CONCLUSION 
Treatment for psoriasis is more important in psoriasis 
patients, because patients are depressed due to abnormal 
appearance and texture of their skin, so they are less likely 
Nadiya Banu et al                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):622-624 
ISSN: 2250-1177                                                                                  [624]                                                                                 CODEN (USA): JDDTAO 
to be involved in other activities due to stress and 
depression.These novel regimens offer patients and their 
caregivers the prospect of more targeted therapeutic 
regimens that offer enhanced clinical outcomes with more 
favorable side-effect profiles. As clinicians and researchers 
build upon this knowledge in the years to come, we can offer 
psoriasis patients an increasingly diverse and powerful 
therapeutic armamentarium. 
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